-
Impact of Diagnosis Delay on Healthcare Resource Utilization (HCRU) among Patients with Pulmonary Arterial Hypertension (PAH)
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Technological Innovation for Chronic Wounds: Pharmacoeconomic Model Based on LOGIT and MAIC Tools
Mar 10, 2025, 14:00 PM -
Analytical Approaches to Estimate Medication Persistence From Electronic Health Record Data: A Study of Tyrosine Kinase Inhibitors in Patients With Epidermal Growth Factor Receptor-Positive Advanced Non-Small Cell Lung Cancer
Mar 10, 2025, 14:00 PM -
Real-world Infusion and Post-Infusion Health Care Resource Use (HCRU) and Costs for CAR T Cell Treatment in Large B-Cell Lymphoma (LBCL): a Comparative Study of Liso-cel Versus Axi-cel
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Pulsed Field Ablation Versus Radiofrequency Ablation and Cryoablation for Paroxysmal Atrial Fibrillation in China
Mar 10, 2025, 14:00 PM -
Identifying Treatment Patterns for Essential Thrombocythemia Using Real-world Data
Mar 10, 2025, 14:00 PM -
Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Mar 10, 2025, 14:00 PM -
Evaluating the Association Between Medicare Star Ratings Part D Medication Adherence Measures and the Part C Plan All-Cause Readmission Outcome Measure
Mar 10, 2025, 14:00 PM -
Evaluation of Real-World Total Healthcare Costs Difference Between Subcutaneous and Intravenous Formulations of Pertuzumab and Trastuzumab in HER2+ Breast Cancer Patients
Mar 10, 2025, 14:00 PM -
Advancing Real World Evidence: Comparative Insights into Global Practices and China's Strategic Progress
Mar 10, 2025, 14:00 PM -
Automating Health Economic Model Quality Check With a Model Generator
Mar 10, 2025, 14:00 PM -
A Reanalysis of Canada's Drug Agency (CDA) Reports: Do Conclusions from Cost-Effectiveness Analyses Using Quality-Adjusted Life-Years (QALYs) Hold When Evaluating with Equal Value of Life-Years Gained (evLYG)?
Mar 10, 2025, 14:00 PM -
Latent Class Analysis (LCA) to Identify Medical Device Usage in Real-World Data
Mar 10, 2025, 14:00 PM -
Real-World Persistence to Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis in a Commercial and Medicare Advantage Population
Mar 10, 2025, 14:00 PM -
Characteristics of Adults With Type 2 Diabetes Who Are Not Treated With A Glucose-Lowering Agent: A Retrospective Cohort Study
Mar 10, 2025, 14:00 PM -
Examining Factors Contributing to Age of Late-Onset Autoimmune Disease in U.S. Adults Using Hierarchical Clustering Mechanisms
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
Mar 10, 2025, 14:00 PM -
Economic and Healthcare Burden in Patients With Fragile X Syndrome: A Systematic Review
Mar 10, 2025, 14:00 PM -
Pre-Diagnostic Healthcare for People with Fragile X Syndrome
Mar 10, 2025, 14:00 PM -
Transfusion Needs For Patients With Myelofibrosis In Latin America
Mar 10, 2025, 14:00 PM
